within Pharmacolibrary.Drugs.ATC.J;

model J01XA05
  extends Pharmacokinetic.Models.PK_3C(
    weight         = 70,
    F              = 1,
    Cl             = 1.31e-06,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0876,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01XA05</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>3</td></tr></table><p>Oritavancin is a semisynthetic lipoglycopeptide antibiotic used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved for use in adults and is administered as a single intravenous dose.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adult subjects receiving a single intravenous dose.</p><h4>References</h4><ol><li><p>Lehoux, D, et al., &amp; Parr, TR (2015). Oritavancin Pharmacokinetics and Bone Penetration in Rabbits. <i>Antimicrobial agents and chemotherapy</i> 59(10) 6501–6505. DOI:<a href=\"https://doi.org/10.1128/AAC.00981-15\">10.1128/AAC.00981-15</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26239977/\">https://pubmed.ncbi.nlm.nih.gov/26239977</a></p></li><li><p>Nau, R, et al., &amp; Eiffert, H (2024). New Antibiotics for the Treatment of Nosocomial Central Nervous System Infections. <i>Antibiotics (Basel, Switzerland)</i> 13(1) –. DOI:<a href=\"https://doi.org/10.3390/antibiotics13010058\">10.3390/antibiotics13010058</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38247617/\">https://pubmed.ncbi.nlm.nih.gov/38247617</a></p></li><li><p>Bhavnani, SM, et al., &amp; Ambrose, PG (2004). Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. <i>Diagnostic microbiology and infectious disease</i> 50(2) 95–102. DOI:<a href=\"https://doi.org/10.1016/j.diagmicrobio.2004.06.007\">10.1016/j.diagmicrobio.2004.06.007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15474317/\">https://pubmed.ncbi.nlm.nih.gov/15474317</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01XA05;
